I
3.12
-0.09 (-2.96%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Indaptus Therapeutics, Inc. | 混合的 | 混合的 |
相关股票
| 股票 | 市值 | DY | P/E（TTM） | P/B |
|---|---|---|---|---|
| INDP | - | - | - | 33.86 |
| SONN | 33 M | - | - | 2.07 |
| CDIO | - | - | - | 0.740 |
| REPL | - | - | - | 10.78 |
| ADXN | - | - | - | 1.30 |
| IFRX | - | - | - | 1.09 |
AIStockmoo 评分
| 价值 35% | -0.8 |
| AI Insight 参考 | NA |
| 相对估值 参考 | NA |
| 财务健康 参考 | -0.8 |
| 时机 35% | 1.3 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | 0.5 |
| 技术平均移动指标 参考 | 2.5 |
| 聪明钱 30% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 内部交易活动 参考 | NA |
| 新闻情绪 参考 | NA |
| 市场环境 | ×0.79 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -23.9% |
| 支柱一致性 | ×0.87 |
| 不计入评分 | |
| 价格波动 参考 | -4.5 |
| 最终评分 | 0.12 |
|
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 36.87% |
| 机构持股比例 | 13.08% |
该时间范围内无数据。
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 24 Sep 2026 | Yahoo Finance |
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
Five smaller stocks with market caps above $100 million beat MRNA’s monthly gain: INDP rose 249%, CYPH 124%, MNOV 85%, GRAL 58% and SRZN 53%. |
| 13 Aug 2026 | Yahoo Finance |
Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a biotechnology company dedicated to immunotherapy research, today announced financial results for the second quarter and six months ended June 30, 2026, and provided a corporate… |
投资组合